Company Information
CIN
Status
Date of Incorporation
06 April 1993
State / ROC
Hyderabad / ROC Hyderabad
Last Balance Sheet
31 March 2023
Last Annual Meeting
30 September 2023
Paid Up Capital
34,500,000
Authorised Capital
100,000,000
Directors
Adi Sesha Giri Jagarapu
Director/Designated Partner
almost 2 years ago
almost 2 years ago
Gopal Reddy Annareddy
Director/Designated Partner
almost 2 years ago
almost 2 years ago
Reddy Narsimha
Director/Designated Partner
almost 2 years ago
almost 2 years ago
Venkatanarasa Reddy Attunuri
Director/Designated Partner
about 2 years ago
about 2 years ago
Parthasaradhi Reddy Bandi
Director/Designated Partner
over 2 years ago
over 2 years ago
Rathnakar Reddy Kura
Director/Designated Partner
over 2 years ago
over 2 years ago
Bandi Vamsikrishna
Director/Designated Partner
over 2 years ago
over 2 years ago
Sambi Reddy Jonnala
Director/Designated Partner
over 2 years ago
over 2 years ago
Kalavathi Bandi
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Ravi Kumar Upputhalla
Company Secretary
over 7 years ago
over 7 years ago
Srinivas Reddy Male
Director
about 14 years ago
about 14 years ago
Past Directors
Srinivas Vengala
Company Secretary
over 7 years ago
over 7 years ago
Gopala Krishna Rampalli
Additional Director
almost 9 years ago
almost 9 years ago
Vijaya Bhaskara Reddy Kesari
Whole Time Director
over 11 years ago
over 11 years ago
Mareddy Pera Reddy
Director
over 22 years ago
over 22 years ago
Patents
The invention provides a novel polymorph of clopidogrel hydrogen sulfate and processes for its preparation.
The present invention relates to novet crystalline forms of abacavir sulfate, to
processes for their preparation and to pharmaceutical compositions containing
them.
Process for Purification of Darbepoetin Alfa
The present invention provides sequential chromatography steps and conditions for purification of a recombinant protein, especially recombinant darbepoetin alfa.
The present invention relates to a process for preparing substituted sulfoxides either as a single enantiomer or in an enantiomerically enriched form Thus, racemic omeprazole is reacted with (S)-camphorsulfonyl chloride to form a diastereomeric mixture and the diastereomers are separated by fractipnal crystallizatio...
The present invention relates to novel hydrate of irbesartan, amorphous irbesartan hydrate and pharmaceutical compositions containing them. The present invention also relates to novel processes for preparing crystalline form-A, crystalline form-B and amorphous form of irbesartan. Thus, for example, irbesartan and wa...
The present invention relates to a process for separation of desired diastereomeric pair from a mixture of diastereomeric pairs thereby obtaining nebivolol intermediates. Thus, the mixture of (+)-[1S*(R*)]-6-fluorO"3,4-dihydro-α-[[phenylmethyl)amino]methyI]-2H-1"benzopyran-2-methanol, (±)-[1S*(S*)]-6-duoro-3,4-dinyd...
The present invention relates to crystalline alfuzosin base and processes for preparation of the said crystalline solid. Thus, for example, alfuzosin base (HPLC purity: 97%) is added to methanol and heated to reflux to form a clear solution, the solution is cooled to 25 - 30°C and stirred for 12 hours at the same te...
The present invention provides solid form of faropenem free acid, its hydrates and processes for their preparation thereof. Thus, for example, dissolving an alkali metal salt of faropenem in water, adjusting the pH of the solution formed with an acid to below about 2.5 and collecting the precipitated solid to obtain...
The present invention discloses novel and stable polymorphs of rimonabant, its hydrates and solvates, to the processes for their preparation and to pharmaceutical compositions comprising them. The present invention further discloses novel and stable amorphous form of rimonabant, process for its preparation and a pha...
The present invention provides an improved and commercially viable
process for preparation of erlotinib substantially free of N-methoxyethyl impurity,
namely N-[(3-ethynylphenyl)-(2-methoxyethyl)]-6,7-bis(2-methoxyethoxy)-4-
quinazolinamine, and its pharmaceutically acceptable acid addition salts thereof in high ...
The present invention relates to a process for obtaining pure aprepitant substantially free of undesired diastereomeric isomer, namely 5-[2(S)-[1(RS)-[3,5-bis(trifluoromethyl)"phenyl)ethoxy]-3-(S)-(4-fluorophenyl)-morpholin-4-yl-methyl]-3,4-dihydro-2H-1,2,4-triazol-3-one. The present invention further provides an im...
The present invention relates to a process for preparing a key intermediate of cefprozil and use of this intermediate in the preparation of cefprozil thereby avoiding impurity-causing self-acylation.
[R"(Z)]-[4-hydroxy-a-[(3-methoxy-1-methyl-3-oxo-1-propenyl)amino]] benzeneacetic acid, mono potassium salt is reacte...
The present invention provides novel crystalline forms of aripiprazole and processes for their preparation.
The present invention provides an enantioselective process for preparing substituted benzimidazoles either as a single enantionr)er or In an enantiomerically enriched form.
The present invention relates to eprosartan mesylate particles having relatively larger surface area, to the methods for the manufacture of said crystalline particles, and to pharmaceutical compositions comprising said crystalline particles. The present invention further relates to crystalline solid of eprosartan ac...
The present invention provides an improved and commercially viable process for the preparation of rimonabant substantially free of amide impurity, namely 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl-4-methyl-pyrazole-3-carboxamide and its pharmaceutically acceptable acid addition salts thereof. Thus, for example, 5-(4-c...
The present invention provides an improved and commercially viable
process for preparation of substantially enaritiomerically pure esomeprazole in
neutral form or as a pharmaceutically acceptable salt or as its solvates including
hydrates. Thus, for example, a compound containing a mixture of 1-(S)-
camphorsulfo...
The present invention provides an improved and commercially viable process for preparation of eprosartan and its pharmaceutically acceptable acid addition salts thereof in high purity and in high yield. Thus, for example, methyl 4-[[2-butyl-5-formyl-1H-imidazol-1-yl] methyl] ben2oate is reacted with ethyl 2-carboxy-...
The present invention relates to two novel and stable crystalline forms of atovaquone, to the processes for their preparation and to pharmaceutical compositions comprising them. The present invention also provides crystalline particles of atovaquone having a specific surface area of from about 0.7 m /g to about 4 m ...
The present invention provides a novel and stable hydrated form of eriotinib free base, and a process for its preparation thereof. The present invention also provides a process for preparation of eriotinib hydrochloride crystalline polymorph A substantially free of polymorph B. The present invention further relates ...
The invention provides a process for preparing intermediate of ezetimibe, which shows hypocholesterolemic activity. Thus 3-[5-(4-fluorophenyl)-1,5-dioxopentyl]-4-phenyl-2-Oxazolidinone is reduced with (-)-DIP chloride to obtain 3-[(5S)-5-(4-fluorophenyl)-5-hydroxy-1-oxopentyl]-4-phenyl-2-Oxazolidinone.
...
The present invention relates to a high assayed esomeprazole magnesium dihydrate substantially free of its trihydrate form. The present invention further provides an improved and commercially viable process for preparation of high assayed esomeprazole magnesium dihydrate substantially free of its trihydrate form. Th...
The present invention provides an improved and efficient process for preparation of highly pure amorphous rabeprazole sodium. Thus, for example, rabeprazole is dissolved in an alcoholic sodium hydroxide solution followed by carbon treatment, the resulting filtrate is distilled under vacuum at 50 - 52°C followed by c...
A novel crystalline form of 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-
piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
(risperidone) and a pharmaceutical composition comprising it.
Valsartan of formula I:is prepared by hydrolysis of valsartan benzyl ester with an alkali metal hydroxide, washing with an organic solvent, acidifying with hydrochloric acid and isolating valsartan from the reaction mixture.
The present invention relates to a process for the preparation of dorzolamide hydrochloride crystalline polymorph. Thus, for example, dissolving dorzolamide free base in dimethylsulfoxide, adding hydrochloric acid, maintaining at 0°C -20°C, adding an alcohol and collecting the solid from the contents by filt...
The present invention relates to novel amorphous and crystalline forms of efavirenz, processes for their preparation and pharmaceutical compositions containing them. In accordance with the present invention efavirenz crude is dissolved in acetone at 25°C - 30°C, the solution is slowly added to water for 30 m...
Registered Trademarks
[Class : 5] Pharmaceutical & Medicinal Preparation
[Class : 5] Medicinal And Pharmaceutical Preparations And Substances
[Class : 5] Medicinal & Pharmaceutical Preparations And Substances, All Goods Being Included In Class 05.
Trade mark is likely to be removed due to non filing of Renewal request within prescribed time limit In case of any discripancy contact respective TM Registry.
View +35 more Brands for Hetero Drugs Limited.
Charges
30 March 2019
State Bank Of India
143 Crore
05 August 2015
State Bank Of Hyderabad
815 Crore
21 March 2005
Industrial Development Bank Of India
81 Crore
05 April 2003
Idbi Bank
11 Crore
14 March 1998
Idbi Bank
4 Crore
14 March 1998
State Bank Of India
560 Crore
01 December 2017
Hdfc Bank Limited
28 Crore
11 November 2002
Bank Of India
2 Crore
29 June 2004
Bank Of India
3 Crore
30 April 2001
Bank Of India
2 Crore
03 February 2004
Bank Of India
2 Crore
26 August 1995
State Bank Of Hyderabad
11 Crore
31 March 2001
State Bank Of India
2 Crore
18 June 1993
State Bank Of Hyderabad
7 Crore
28 June 2008
State Bank Of India
50 Crore
30 June 1994
State Bank Of Hyderabad
7 Crore
03 April 2002
State Bank Of Mysore
2 Crore
12 February 2002
State Bank Of Musore
2 Crore
12 January 2002
State Bank Of Musore
3 Crore
28 June 2003
State Bank Of Mysore
1 Crore
29 October 2010
State Bank Of India
50 Crore
12 January 2002
State Bank Of Mysore
3 Crore
12 February 2002
State Bank Of Mysore
2 Crore
29 December 2008
State Bank Of Hyderabad
354 Crore
18 June 1993
Andhra Bank
4 Crore
02 January 2008
State Bank Of Hyderabad
253 Crore
12 August 2003
State Bank Of India
2 Crore
30 June 1994
State Bank Of Hyderabad
7 Crore
19 March 2014
State Bank Of India
84 Crore
18 October 2008
Bank Of India Limited
75 Crore
26 July 2012
Dbs Bank Limited
100 Crore
30 March 2011
State Bank Of Hyderabad
50 Crore
13 December 2007
State Bank Of Mysore
455 Crore
20 February 2008
State Bank Of Mysore
30 Crore
12 January 2007
State Bank Of Indore
30 Crore
16 October 2006
State Bank Of Mysore
30 Crore
16 December 2004
Andhra Bank
30 Crore
05 April 2003
Idbi Bank Ltd.
11 Crore
28 June 2003
State Bank Of Musore
10 Crore
16 May 2003
Idbi Bank Limited
1 Crore
01 August 2001
Industrial Development Bank Of India
6 Crore
18 October 1994
Industrial Development Bank Of India
3 Crore
11 September 1995
Industrial Development Bank Of India
3 Crore
24 December 1996
Idbi Bank Ltd.
2 Crore
02 February 2021
Hdfc Bank Limited
12 Lak
04 December 2020
Hdfc Bank Limited
14 Lak
04 December 2020
Hdfc Bank Limited
14 Lak
18 August 2020
Mahindra And Mahindra Financial Services Limited
4 Crore
07 December 2019
Hdfc Bank Limited
2 Crore
26 June 2020
State Bank Of India
5 Crore
28 June 2023
State Bank Of India
0
23 January 2023
Others
0
29 September 2022
Others
0
29 September 2022
Others
0
27 July 2022
Others
0
14 March 1998
State Bank Of India
0
30 March 2019
State Bank Of India
0
05 August 2015
State Bank Of Hyderabad
0
21 October 2021
Idbi Trusteeship Services Limited
0
02 February 2021
Hdfc Bank Limited
0
04 December 2020
Hdfc Bank Limited
0
20 February 2008
State Bank Of Mysore
0
04 December 2020
Hdfc Bank Limited
0
18 August 2020
Others
0
30 June 1994
State Bank Of Hyderabad
0
07 December 2019
Hdfc Bank Limited
0
01 December 2017
Hdfc Bank Limited
0
26 June 2020
State Bank Of India
0
02 January 2008
State Bank Of Hyderabad
0
12 August 2003
State Bank Of India
0
16 May 2003
Idbi Bank Limited
0
05 April 2003
Idbi Bank
0
12 February 2002
State Bank Of Mysore
0
18 June 1993
Andhra Bank
0
21 March 2005
Industrial Development Bank Of India
0
03 February 2004
Bank Of India
0
28 June 2003
State Bank Of Musore
0
05 April 2003
Idbi Bank Ltd.
0
24 December 1996
Idbi Bank Ltd.
0
01 August 2001
Industrial Development Bank Of India
0
11 September 1995
Industrial Development Bank Of India
0
18 October 1994
Industrial Development Bank Of India
0
19 March 2014
State Bank Of India
0
26 July 2012
Dbs Bank Limited
0
30 March 2011
State Bank Of Hyderabad
0
29 December 2008
State Bank Of Hyderabad
0
18 October 2008
Bank Of India Limited
0
31 March 2001
State Bank Of India
0
28 June 2008
State Bank Of India
0
14 March 1998
Idbi Bank
0
18 June 1993
State Bank Of Hyderabad
0
26 August 1995
State Bank Of Hyderabad
0
12 January 2007
State Bank Of Indore
0
28 June 2003
State Bank Of Mysore
0
30 April 2001
Bank Of India
0
11 November 2002
Bank Of India
0
29 June 2004
Bank Of India
0
30 June 1994
State Bank Of Hyderabad
0
13 December 2007
State Bank Of Mysore
0
03 April 2002
State Bank Of Mysore
0
16 December 2004
Andhra Bank
0
12 January 2002
State Bank Of Mysore
0
29 October 2010
State Bank Of India
0
12 February 2002
State Bank Of Musore
0
12 January 2002
State Bank Of Musore
0
16 October 2006
State Bank Of Mysore
0
28 June 2023
State Bank Of India
0
23 January 2023
Others
0
29 September 2022
Others
0
29 September 2022
Others
0
27 July 2022
Others
0
14 March 1998
State Bank Of India
0
30 March 2019
State Bank Of India
0
05 August 2015
State Bank Of Hyderabad
0
21 October 2021
Idbi Trusteeship Services Limited
0
02 February 2021
Hdfc Bank Limited
0
04 December 2020
Hdfc Bank Limited
0
20 February 2008
State Bank Of Mysore
0
04 December 2020
Hdfc Bank Limited
0
18 August 2020
Others
0
30 June 1994
State Bank Of Hyderabad
0
07 December 2019
Hdfc Bank Limited
0
01 December 2017
Hdfc Bank Limited
0
26 June 2020
State Bank Of India
0
02 January 2008
State Bank Of Hyderabad
0
12 August 2003
State Bank Of India
0
16 May 2003
Idbi Bank Limited
0
05 April 2003
Idbi Bank
0
12 February 2002
State Bank Of Mysore
0
18 June 1993
Andhra Bank
0
21 March 2005
Industrial Development Bank Of India
0
03 February 2004
Bank Of India
0
28 June 2003
State Bank Of Musore
0
05 April 2003
Idbi Bank Ltd.
0
24 December 1996
Idbi Bank Ltd.
0
01 August 2001
Industrial Development Bank Of India
0
11 September 1995
Industrial Development Bank Of India
0
18 October 1994
Industrial Development Bank Of India
0
19 March 2014
State Bank Of India
0
26 July 2012
Dbs Bank Limited
0
30 March 2011
State Bank Of Hyderabad
0
29 December 2008
State Bank Of Hyderabad
0
18 October 2008
Bank Of India Limited
0
31 March 2001
State Bank Of India
0
28 June 2008
State Bank Of India
0
14 March 1998
Idbi Bank
0
18 June 1993
State Bank Of Hyderabad
0
26 August 1995
State Bank Of Hyderabad
0
12 January 2007
State Bank Of Indore
0
28 June 2003
State Bank Of Mysore
0
30 April 2001
Bank Of India
0
11 November 2002
Bank Of India
0
29 June 2004
Bank Of India
0
30 June 1994
State Bank Of Hyderabad
0
13 December 2007
State Bank Of Mysore
0
03 April 2002
State Bank Of Mysore
0
16 December 2004
Andhra Bank
0
12 January 2002
State Bank Of Mysore
0
29 October 2010
State Bank Of India
0
12 February 2002
State Bank Of Musore
0
12 January 2002
State Bank Of Musore
0
16 October 2006
State Bank Of Mysore
0
Documents
Form MGT-14-04042021_signed
Form MGT-7-03042021_signed
Copy of MGT-8-30122020
List of share holders, debenture holders;-30122020
Form MGT-14-29122020_signed
Optional Attachment-(3)-29122020
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-29122020
Optional Attachment-(1)-29122020
Optional Attachment-(2)-29122020
Optional Attachment-(1)-02122020
Instrument(s) of creation or modification of charge;-02122020
Form CHG-1-02122020_signed
CERTIFICATE OF REGISTRATION OF CHARGE-20201202
Form CHG-1-31102020_signed
CERTIFICATE OF REGISTRATION FOR MODIFICATION OF CHARGE-20201031
Instrument(s) of creation or modification of charge;-29102020
Form CHG-1-28102020_signed
CERTIFICATE OF REGISTRATION FOR MODIFICATION OF CHARGE-20201028
Instrument(s) of creation or modification of charge;-27102020
Particulars of all joint charge holders;-27102020
Form MR-1-25072020_signed
Form CHG-1-25072020_signed
Form MR-1-24072020_signed
Copy of letter of consent to act as Managing Director/ Whole time Director/Manager ; -24072020
Copy of shareholders resolution-24072020
Instrument(s) of creation or modification of charge;-24072020
CERTIFICATE OF REGISTRATION OF CHARGE-20200724
Form MGT-14-18072020_signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-17072020
Optional Attachment-(1)-17072020
